AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

🍀

AVITA Medical GAAP EPS of -$0.21 beats by $0.07, revenue of $9.46M beats by $0.63M https://seekingalpha.com/news/3940180-avita-medical-gaap-eps-of-0_21-beats-0_07-revenue-of-9_46m-beats-0_63m • AVITA Medical press release (NASDAQ:RCEL): Q4 GAAP EPS of -$0.21 beats by $0.07. • Revenue of $9.46M (+36.3% Y/Y) beats by $0.63M. • Our commercial revenue, which excludes BARDA revenue, increased by 37% to $9.4 million in the three months ended December 31, 2022, compared to $6.8 million in the same period in 2021.

AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-fourth-quarter-and-full-year-2022

AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call https://www.globenewswire.com/news-release/2023/01/19/2592133/0/en/AVITA-Medical-Announces-Management-Changes-and-Fourth-Quarter-2022-Earnings-Conference-Call.html

https://m.marketscreener.com/quote/stock/AVITA-MEDICAL-INC-8777378/news/Avita-Medical-Files-Vitiligo-Indication-for-Skin-Restoration-Therapy-with-US-FDA-Shares-Fall-5-42574666/

AVH Avita Medical Inc Says Submits FDA PMA Application To Expand Indication To Vitiligo https://hotcopper.com.au/threads/news-avh-avita-medical-inc-says-submits-fda-pma-application-to-expand-indication-to-vitiligo.7152291/ AVITA Medical Inc RCEL.O : • SUBMITS FDA PMA APPLICATION TO EXPAND INDICATION TO VITILIGO • ANTICIPATE FULL LAUNCH OF THIS TREATMENT OPTION IN JANUARY 2025 • APPLICATION, IF APPROVED, WILL EXPAND THE INDICATION OF RECELL TO INCLUDE THE TREATMENT OF STABLE VITILIGO

●●●Nach der Zulassung erweitert diese Indikation unsere derzeitigen Marktchancen um mindestens das Dreifache und wird voraussichtlich ab Juli 2023 eine bedeutende Wachstumschance für uns darstellen.●●● Das wäre schon ein guter Anfang 👌

https://www.globenewswire.com/news-release/2022/12/13/2572325/0/en/AVITA-Medical-Announces-Results-of-2022-Annual-Meeting-of-Stockholders.html

AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair https://www.globenewswire.com/news-release/2022/12/12/2571977/0/en/AVITA-Medical-Submits-FDA-PMA-Supplement-to-Further-Expand-Indication-to-Soft-Tissue-Repair.html

Link zum Download der Präsentation von der Jahreshauptversammlung: 2022 Annual Meeting of Stockholders Presentation https://hotcopper.com.au/threads/ann-2022-annual-meeting-of-stockholders-presentation.7143595/

https://www.globenewswire.com/news-release/2022/11/21/2560279/0/en/AVITA-Medical-to-Present-at-the-Piper-Sandler-34th-Annual-Healthcare-Conference.html AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference ...announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time. ...

https://www.einnews.com/pr_news/601735565/avita-medical-to-host-investor-webinar-briefing AVITA Medical® to Host Investor Webinar Briefing ...invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, CEO, and Michael Holder, CFO, on November 23, 2022 at 4:00pm (PST) / November 24, 2022 at 11:00am (AEDT). ....

Das könnte wirklich was werden. Danke für die regelmäßigen Updates!

https://www.globenewswire.com/news-release/2022/11/10/2553735/0/en/AVITA-Medical-Reports-Third-Quarter-2022-Financial-Results.html

https://themarketherald.com.au/avita-medical-asxavh-bolsters-revenue-guidance-reduces-quarterly-net-loss-2022-11-11/ Avita Medical (ASX:AVH) bolsters revenue guidance, reduces quarterly net loss

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair https://www.globenewswire.com/news-release/2022/11/09/2552596/0/en/AVITA-Medical-Announces-Achievement-of-Co-Primary-Endpoints-in-Updated-Analysis-of-Pivotal-Trial-of-RECELL-System-for-Soft-Tissue-Repair.html